+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Kaposi Sarcoma - Global Market Trajectory & Analytics

  • ID: 5139865
  • Report
  • April 2021
  • Region: Global
  • 138 pages
  • Global Industry Analysts, Inc
Global Kaposi Sarcoma Market to Reach $146.5 Million by 2027

Amid the COVID-19 crisis, the global market for Kaposi Sarcoma estimated at US$125.4 Million in the year 2020, is projected to reach a revised size of US$146.5 Million by 2027, growing at a CAGR of 2.2% over the analysis period 2020-2027. HAART, one of the segments analyzed in the report, is projected to record a 2.2% CAGR and reach US$86.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Chemotherapy segment is readjusted to a revised 1.9% CAGR for the next 7-year period.



The U.S. Market is Estimated at $36.9 Million, While China is Forecast to Grow at 1.8% CAGR

The Kaposi Sarcoma market in the U.S. is estimated at US$36.9 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$25.6 Million by the year 2027 trailing a CAGR of 1.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 1.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Immunotherapy Segment to Record 2.7% CAGR

In the global Immunotherapy segment, USA, Canada, Japan, China and Europe will drive the 2.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$16.4 Million in the year 2020 will reach a projected size of US$19.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$16.6 Million by the year 2027.

Select Competitors (Total 51 Featured):
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Kaposi Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for HAART by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for HAART by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for HAART by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • Table 13: USA Current & Future Analysis for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 14: USA Historic Review for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 15: USA 15-Year Perspective for Kaposi Sarcoma by Segment - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027
  • Table 16: Canada Current & Future Analysis for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 17: Canada Historic Review for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 18: Canada 15-Year Perspective for Kaposi Sarcoma by Segment - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027
  • Table 19: Japan Current & Future Analysis for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 20: Japan Historic Review for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 21: Japan 15-Year Perspective for Kaposi Sarcoma by Segment - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027
  • Table 22: China Current & Future Analysis for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 23: China Historic Review for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 24: China 15-Year Perspective for Kaposi Sarcoma by Segment - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027
  • Table 25: Europe Current & Future Analysis for Kaposi Sarcoma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 26: Europe Historic Review for Kaposi Sarcoma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 27: Europe 15-Year Perspective for Kaposi Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 28: Europe Current & Future Analysis for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 29: Europe Historic Review for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 30: Europe 15-Year Perspective for Kaposi Sarcoma by Segment - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027
  • Table 31: France Current & Future Analysis for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 32: France Historic Review for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 33: France 15-Year Perspective for Kaposi Sarcoma by Segment - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027
  • Table 34: Germany Current & Future Analysis for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 35: Germany Historic Review for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 36: Germany 15-Year Perspective for Kaposi Sarcoma by Segment - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027
  • Table 37: Italy Current & Future Analysis for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 38: Italy Historic Review for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 39: Italy 15-Year Perspective for Kaposi Sarcoma by Segment - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027
  • Table 40: UK Current & Future Analysis for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 41: UK Historic Review for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 42: UK 15-Year Perspective for Kaposi Sarcoma by Segment - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027
  • Table 43: Rest of Europe Current & Future Analysis for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 44: Rest of Europe Historic Review for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 45: Rest of Europe 15-Year Perspective for Kaposi Sarcoma by Segment - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027
  • Table 46: Asia-Pacific Current & Future Analysis for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 47: Asia-Pacific Historic Review for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 48: Asia-Pacific 15-Year Perspective for Kaposi Sarcoma by Segment - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027
  • Table 49: Rest of World Current & Future Analysis for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 50: Rest of World Historic Review for Kaposi Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
  • Table 51: Rest of World 15-Year Perspective for Kaposi Sarcoma by Segment - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 51
Note: Product cover images may vary from those shown
Adroll
adroll